Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Goodrich Q4 Profit Rises - Quick Facts

Goodrich Corp. (GR: Quote) reported fourth quarter net income of $237.9 million or $1.85 per share, up from $148.3 million, or $1.16 per share in the year ago quarter.

The increase in net income is attributable primarily to the impact of sales growth in all of the company's major market channels, strong operational performance, and ongoing success on continuous improvement initiatives.

Sales were $2.145 billion, up from $1.806 billion in the year ago quarter.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.57 per share on revenues of $2.13 billion for the quarter. Analysts' estimates typically exclude special items.

Click here to receive FREE breaking news email alerts for Goodrich Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving moderately lower in early trading on Monday, stocks have seen further downside as the trading day has progressed. With the drop on the day, the Dow has pulled back well off last Friday's record closing high. After reporting four consecutive monthly increases, the National Association of Realtors released a report on Monday showing an unexpected drop in U.S. existing home sales in the month of August. NAR said existing home sales fell 1.8 percent to a seasonally adjusted annual rate of 5.05 million in August. The European Central Bank remains ready to use additional unconventional tools to counter risks to the inflation outlook and to boost the euro area economy, ECB President Mario Draghi said on Monday. "The Governing Council remains fully determined to counter risks to the medium-term outlook for inflation," Draghi said in Brussels.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.